Novo Nordisk, Kakao Health sign digital healthcare MOU

for obesity and diabetes

"Will leverage digital technology to improve the treatment journey of obesity and diabetes patients"

Kakao Healthcare (CEO Hee Hwang) announced on the 3rd that it has signed a memorandum of understanding with the multinational pharmaceutical company, Novo Nordisk Korea (General Manager Kasper Roseeuw Poulsen) to build a digital healthcare ecosystem for obesity and diabetes patients.

 

The signing ceremony, held on September 2 at Novo Nordisk Korea’s headquarters in Songpa-gu, Seoul, was attended by Kakao Healthcare CEO Hee Hwang and Novo Nordisk Korea CEO Kasper Rosseeu Poulsen.

 

At the event, the two companies agreed to collaborate by utilizing various digital technologies to improve the treatment journey of obesity and diabetes patients, ultimately creating a sustainable treatment environment that can deliver better outcomes.

 

This is the second collaboration between the two companies, following their first partnership in 2023.

 

Under the agreement, they linked Kakao Healthcare’s AI-based health management app ‘Pasta’ with Novo Nordisk’s insulin FlexTouch pen and its smart cap ‘Mallya,’ providing a medication management solution for diabetes patients.

 

The new partnership is significant in that it expands the scope of collaboration from diabetes to obesity, creating a comprehensive alliance.

 

The companies plan to address the unmet medical needs of Korea’s rapidly growing obesity and diabetes populations by offering patient-centered digital solutions.

 

Specifically, in the field of obesity, the partnership will focus on ▲developing a personalized digital support program, ▲providing solutions to improve treatment effectiveness and quality of life.

 

and In particular, the partnership will integrate Novo Nordisk’s patient support program Novo Fit Care, which is offered to patients prescribed its obesity treatments, into the Pasta app.

 

Through this, patients will be able to manage weight and other long-term health aspects in a comprehensive way.

 

In the field of diabetes, the companies will jointly develop digital solutions aimed at improving disease awareness.

 

Kasper Roseeuw Poulsen, General Manager of Novo Nordisk Korea, said, "Obesity and diabetes are chronic conditions which, if left untreated, can lead to serious comorbidities and impose a tremendous burden on individuals and society.

 

With Novo Nordisk’s more than 100 years of dedication to diabetes and obesity, and Kakao Healthcare’s leadership in Korea’s digital healthcare sector, the partnership will further accelerate integrated innovation for patient support in Korea." Hee Hwang, CEO of Kakao Healthcare, said, "Kakao Healthcare has leveraged AI, big data, and other technologies to bring positive changes to patients’ health journeys.

 

By combining this experience and technology with Novo Nordisk, a global leader in obesity and diabetes care, we aim to play a major role in expanding patient-centered digital healthcare on a global scale."